NasdaqGS:TYRABiotechs
Tyra Biosciences (TYRA) Valuation Under Review After ASCO Catalysts And Positive Analyst Attention
Analyst attention and ASCO presentations put Tyra Biosciences in focus
Tyra Biosciences (TYRA) has moved into the spotlight after new positive analyst coverage, alongside progress in its dabogratinib program, including accepted abstracts at the 2026 ASCO Genitourinary Cancers Symposium and ongoing Phase 2 trials.
See our latest analysis for Tyra Biosciences.
Those ASCO and conference appearances sit against a backdrop of strong momentum, with the share price at US$33.31, a 90 day share price...